Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurons | 16 | 2023 | 1130 | 1.630 |
Why?
|
| Hippocampus | 5 | 2011 | 546 | 1.040 |
Why?
|
| Essential Tremor | 1 | 2023 | 2 | 0.970 |
Why?
|
| Tremor | 1 | 2023 | 7 | 0.960 |
Why?
|
| Nicotine | 8 | 2017 | 238 | 0.840 |
Why?
|
| Alzheimer Disease | 5 | 2013 | 881 | 0.810 |
Why?
|
| Depression | 4 | 2019 | 664 | 0.700 |
Why?
|
| Amyloid beta-Protein Precursor | 5 | 2013 | 95 | 0.680 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 2010 | 72 | 0.670 |
Why?
|
| Brain | 3 | 2016 | 1268 | 0.650 |
Why?
|
| Neuropeptides | 3 | 2007 | 57 | 0.610 |
Why?
|
| Locus Coeruleus | 5 | 2011 | 15 | 0.610 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2009 | 184 | 0.600 |
Why?
|
| Presenilin-1 | 4 | 2011 | 27 | 0.590 |
Why?
|
| Astrocytes | 2 | 2016 | 203 | 0.590 |
Why?
|
| Nicotinic Agonists | 6 | 2017 | 68 | 0.570 |
Why?
|
| Antidepressive Agents | 3 | 2019 | 53 | 0.550 |
Why?
|
| Hypothalamus | 3 | 2007 | 122 | 0.540 |
Why?
|
| Copper | 1 | 2016 | 101 | 0.540 |
Why?
|
| Aging | 2 | 2011 | 639 | 0.510 |
Why?
|
| Neuroprotective Agents | 2 | 2022 | 231 | 0.510 |
Why?
|
| Disease Models, Animal | 9 | 2013 | 1300 | 0.440 |
Why?
|
| Animals | 25 | 2023 | 14307 | 0.440 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2010 | 40 | 0.380 |
Why?
|
| Parkinson Disease | 3 | 2022 | 167 | 0.380 |
Why?
|
| Mice | 12 | 2023 | 5668 | 0.360 |
Why?
|
| Mice, Transgenic | 5 | 2011 | 608 | 0.340 |
Why?
|
| Estradiol | 1 | 2011 | 244 | 0.340 |
Why?
|
| Immunohistochemistry | 5 | 2011 | 859 | 0.320 |
Why?
|
| Nerve Degeneration | 2 | 2010 | 101 | 0.320 |
Why?
|
| Sleep, REM | 1 | 2007 | 11 | 0.310 |
Why?
|
| Sleep Deprivation | 1 | 2007 | 23 | 0.300 |
Why?
|
| Ethanol | 4 | 2017 | 188 | 0.290 |
Why?
|
| Rats | 10 | 2016 | 3261 | 0.280 |
Why?
|
| Central Nervous System Depressants | 3 | 2017 | 37 | 0.270 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2005 | 25 | 0.260 |
Why?
|
| Cerebral Cortex | 4 | 2010 | 274 | 0.260 |
Why?
|
| Bipolar Disorder | 1 | 2005 | 46 | 0.260 |
Why?
|
| Species Specificity | 3 | 2016 | 233 | 0.250 |
Why?
|
| Neuroblastoma | 2 | 2022 | 128 | 0.250 |
Why?
|
| Harmaline | 1 | 2023 | 1 | 0.240 |
Why?
|
| Sulpiride | 1 | 2023 | 6 | 0.240 |
Why?
|
| Cell Count | 7 | 2014 | 129 | 0.240 |
Why?
|
| Depressive Disorder, Major | 1 | 2005 | 102 | 0.240 |
Why?
|
| Rats, Inbred WKY | 3 | 2009 | 23 | 0.230 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 4 | 2009 | 131 | 0.230 |
Why?
|
| Rats, Wistar | 3 | 2009 | 202 | 0.220 |
Why?
|
| Cerebellum | 3 | 2010 | 69 | 0.210 |
Why?
|
| Male | 14 | 2016 | 18870 | 0.200 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 119 | 0.200 |
Why?
|
| Gyrus Cinguli | 2 | 2011 | 23 | 0.200 |
Why?
|
| Antiparkinson Agents | 1 | 2019 | 11 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 2 | 2023 | 1530 | 0.180 |
Why?
|
| Nerve Growth Factors | 1 | 2019 | 33 | 0.180 |
Why?
|
| Female | 14 | 2013 | 19873 | 0.170 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2016 | 1534 | 0.170 |
Why?
|
| Analysis of Variance | 4 | 2009 | 528 | 0.170 |
Why?
|
| Humans | 15 | 2023 | 34853 | 0.160 |
Why?
|
| Medulla Oblongata | 2 | 2010 | 33 | 0.160 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2017 | 17 | 0.150 |
Why?
|
| Neurotransmitter Agents | 1 | 2017 | 57 | 0.150 |
Why?
|
| X-Rays | 1 | 2016 | 17 | 0.150 |
Why?
|
| Molecular Imaging | 1 | 2016 | 30 | 0.140 |
Why?
|
| Fluorescence | 1 | 2016 | 117 | 0.140 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 68 | 0.140 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2016 | 75 | 0.130 |
Why?
|
| Afferent Pathways | 1 | 2014 | 33 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 183 | 0.130 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2013 | 5 | 0.120 |
Why?
|
| Presenilins | 1 | 2013 | 6 | 0.120 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 65 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 82 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 145 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2013 | 834 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 984 | 0.100 |
Why?
|
| Substantia Nigra | 2 | 2010 | 41 | 0.100 |
Why?
|
| Hyperkinesis | 1 | 2010 | 6 | 0.100 |
Why?
|
| Prion Diseases | 1 | 2010 | 9 | 0.100 |
Why?
|
| Prions | 1 | 2010 | 25 | 0.100 |
Why?
|
| Ovariectomy | 1 | 2011 | 104 | 0.100 |
Why?
|
| Neostriatum | 1 | 2010 | 25 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2010 | 91 | 0.100 |
Why?
|
| Hominidae | 1 | 2010 | 11 | 0.100 |
Why?
|
| Anatomy, Comparative | 1 | 2010 | 4 | 0.100 |
Why?
|
| Gorilla gorilla | 1 | 2010 | 4 | 0.100 |
Why?
|
| Hylobates | 1 | 2010 | 3 | 0.090 |
Why?
|
| Neocortex | 1 | 2010 | 26 | 0.090 |
Why?
|
| Frontal Lobe | 1 | 2010 | 49 | 0.090 |
Why?
|
| Pan troglodytes | 1 | 2010 | 21 | 0.090 |
Why?
|
| Immobility Response, Tonic | 1 | 2009 | 1 | 0.090 |
Why?
|
| Flavonols | 1 | 2009 | 15 | 0.090 |
Why?
|
| Stereotaxic Techniques | 1 | 2009 | 20 | 0.090 |
Why?
|
| Gliosis | 2 | 2010 | 22 | 0.090 |
Why?
|
| Macaca mulatta | 1 | 2010 | 122 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2016 | 1802 | 0.090 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2009 | 24 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2006 | 92 | 0.090 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2009 | 58 | 0.090 |
Why?
|
| Swimming | 1 | 2009 | 37 | 0.090 |
Why?
|
| Exploratory Behavior | 1 | 2009 | 72 | 0.090 |
Why?
|
| Disease Progression | 1 | 2011 | 580 | 0.090 |
Why?
|
| Mesencephalon | 3 | 2010 | 41 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 325 | 0.080 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2008 | 12 | 0.080 |
Why?
|
| Time Factors | 2 | 2010 | 1681 | 0.080 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2022 | 70 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 2128 | 0.080 |
Why?
|
| Catecholamines | 1 | 2007 | 43 | 0.080 |
Why?
|
| Ventral Tegmental Area | 1 | 2007 | 36 | 0.080 |
Why?
|
| Phencyclidine Abuse | 1 | 2006 | 1 | 0.070 |
Why?
|
| Phencyclidine | 1 | 2006 | 17 | 0.070 |
Why?
|
| Schizophrenic Psychology | 1 | 2006 | 17 | 0.070 |
Why?
|
| Motor Activity | 1 | 2009 | 393 | 0.070 |
Why?
|
| Sarcosine | 1 | 2006 | 2 | 0.070 |
Why?
|
| Dopamine | 2 | 2022 | 232 | 0.070 |
Why?
|
| Serine | 1 | 2006 | 72 | 0.070 |
Why?
|
| Body Weight | 1 | 2007 | 404 | 0.070 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 141 | 0.070 |
Why?
|
| Receptors, Neuropeptide | 1 | 2004 | 5 | 0.070 |
Why?
|
| Phrenic Nerve | 1 | 2004 | 17 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2006 | 137 | 0.060 |
Why?
|
| Cell Size | 1 | 2004 | 42 | 0.060 |
Why?
|
| Respiration | 1 | 2004 | 49 | 0.060 |
Why?
|
| Motor Neurons | 1 | 2004 | 72 | 0.060 |
Why?
|
| Spinal Cord | 1 | 2004 | 85 | 0.060 |
Why?
|
| Neural Pathways | 1 | 2004 | 120 | 0.060 |
Why?
|
| Cell Death | 1 | 2005 | 260 | 0.060 |
Why?
|
| Neurotoxins | 2 | 2008 | 52 | 0.060 |
Why?
|
| Aconitine | 1 | 2003 | 2 | 0.060 |
Why?
|
| Mutation | 1 | 2007 | 1023 | 0.050 |
Why?
|
| Vitamin A | 1 | 2023 | 87 | 0.050 |
Why?
|
| Vitamins | 1 | 2023 | 91 | 0.050 |
Why?
|
| Cell Survival | 2 | 2017 | 818 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2005 | 1056 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2009 | 1442 | 0.050 |
Why?
|
| Vitamin D | 1 | 2023 | 176 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 968 | 0.050 |
Why?
|
| Behavior, Animal | 2 | 2013 | 304 | 0.050 |
Why?
|
| Functional Laterality | 2 | 2010 | 75 | 0.040 |
Why?
|
| Mecamylamine | 2 | 2013 | 14 | 0.040 |
Why?
|
| Nicotinic Antagonists | 2 | 2013 | 28 | 0.040 |
Why?
|
| Aged | 3 | 2008 | 6448 | 0.040 |
Why?
|
| MPTP Poisoning | 1 | 1997 | 10 | 0.040 |
Why?
|
| Acoustic Stimulation | 2 | 2008 | 58 | 0.040 |
Why?
|
| Apoptosis | 1 | 2005 | 1317 | 0.040 |
Why?
|
| Fluoresceins | 1 | 2017 | 27 | 0.040 |
Why?
|
| Dizocilpine Maleate | 2 | 2008 | 45 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 1997 | 88 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2017 | 89 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 606 | 0.040 |
Why?
|
| Sclera | 1 | 2016 | 6 | 0.040 |
Why?
|
| Trabecular Meshwork | 1 | 2016 | 11 | 0.040 |
Why?
|
| Optic Nerve | 1 | 2016 | 28 | 0.040 |
Why?
|
| Aqueous Humor | 1 | 2016 | 18 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2016 | 61 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 1997 | 197 | 0.040 |
Why?
|
| Middle Aged | 3 | 2008 | 9642 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 2016 | 121 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 146 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 1997 | 287 | 0.030 |
Why?
|
| Arousal | 2 | 2006 | 82 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 1997 | 338 | 0.030 |
Why?
|
| Receptors, Nicotinic | 2 | 2008 | 91 | 0.030 |
Why?
|
| Pregnancy | 3 | 2005 | 1503 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2014 | 74 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 445 | 0.030 |
Why?
|
| Computational Biology | 1 | 2016 | 275 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1997 | 164 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 78 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 1997 | 1152 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 600 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2013 | 129 | 0.030 |
Why?
|
| Memory | 1 | 2013 | 165 | 0.030 |
Why?
|
| Growth and Development | 1 | 2011 | 8 | 0.030 |
Why?
|
| Primates | 1 | 2011 | 36 | 0.020 |
Why?
|
| Parvalbumins | 1 | 2010 | 15 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2010 | 47 | 0.020 |
Why?
|
| Autonomic Nervous System | 1 | 2010 | 36 | 0.020 |
Why?
|
| Serotonin | 1 | 2010 | 114 | 0.020 |
Why?
|
| Kaempferols | 1 | 2009 | 2 | 0.020 |
Why?
|
| Choline | 1 | 2010 | 57 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2009 | 50 | 0.020 |
Why?
|
| Adult | 1 | 2005 | 11034 | 0.020 |
Why?
|
| Quercetin | 1 | 2009 | 41 | 0.020 |
Why?
|
| Homeostasis | 1 | 2010 | 172 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 135 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2008 | 19 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 2008 | 12 | 0.020 |
Why?
|
| Longevity | 1 | 2010 | 143 | 0.020 |
Why?
|
| Isotopes | 1 | 2008 | 8 | 0.020 |
Why?
|
| Muscarinic Agonists | 1 | 2008 | 10 | 0.020 |
Why?
|
| Scopolamine | 1 | 2008 | 4 | 0.020 |
Why?
|
| Bungarotoxins | 1 | 2008 | 21 | 0.020 |
Why?
|
| Pilocarpine | 1 | 2008 | 8 | 0.020 |
Why?
|
| Muscarinic Antagonists | 1 | 2008 | 12 | 0.020 |
Why?
|
| Computer Graphics | 1 | 1988 | 16 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 642 | 0.020 |
Why?
|
| Pyridines | 1 | 2008 | 113 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 34 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2009 | 878 | 0.020 |
Why?
|
| Electroshock | 1 | 2006 | 16 | 0.020 |
Why?
|
| Cognition | 1 | 2009 | 373 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2009 | 486 | 0.020 |
Why?
|
| Seizures | 1 | 2006 | 67 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2006 | 137 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2006 | 323 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 913 | 0.020 |
Why?
|
| Caspases | 1 | 2005 | 132 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 649 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2004 | 69 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2005 | 194 | 0.020 |
Why?
|
| Age Factors | 1 | 2006 | 1007 | 0.010 |
Why?
|
| Sex Factors | 1 | 2006 | 859 | 0.010 |
Why?
|
| Dihydro-beta-Erythroidine | 1 | 2003 | 4 | 0.010 |
Why?
|
| Culture Media | 1 | 2003 | 84 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 59 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 2333 | 0.010 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 1997 | 45 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1997 | 125 | 0.010 |
Why?
|